Pre-myeloid Cancer and Bone Marrow Failure Clinic Study

Launched by MAYO CLINIC · Nov 4, 2016

Keywords

ClinConnect Summary

The Pre-myeloid Cancer and Bone Marrow Failure Clinic Study is a clinical trial aimed at finding out how well a test called next generation sequencing (NGS) can detect early signs of certain blood cancers and conditions that affect bone marrow. This test looks at specific genes related to these health issues and helps doctors identify patients who might be at risk of developing serious conditions like myeloid cancers or bone marrow failure. By catching these issues early, doctors hope to provide treatments sooner, which could improve outcomes for patients.

To participate in this trial, you may be eligible if you have certain blood conditions that are not fully understood, such as idiopathic cytopenias or clonal hematopoiesis, or if you have a family history of these conditions. The study is open to adults aged 65 to 74, and it welcomes patients as well as family members of patients with these conditions. If you join the trial, you can expect to undergo genetic testing to help determine your risk level. This study is currently recruiting participants, and it could be an important step in understanding and potentially preventing serious health issues related to blood and bone marrow.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with idiopathic cytopenias of unclear significance (ICUS)
• • Patients with clonal hematopoiesis of indeterminate significance (clonal hematopoiesis of indeterminate potential \[CHIP\]), including the recently described CHIP syndrome called VEXAS (vacuoles, E1 ubiquitin ligase, X chromosomal, autoimmune and somatic)
• • Patients with clonal cytopenias of undetermined significance (CCUS)
• • Marrow failure syndromes with myeloid malignancy predisposition - telomere dysfunction, chromosomal breakage disorders
• • Germ line inherited syndromes with risk for malignant transformation - GATA2, CEBPA, ETV-6, RUNX1, JAK2, PF6, etc.
• • Low risk MDS (idiopathic dysplasia of unclear significance)
• • Family member of a patient with one of the above conditions
• • Patient at high risk or suspected of developing one of the above conditions
• Exclusion Criteria:
• • Patients under 18 years of age